Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) FCF Margin: 2020-2025

Historic FCF Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 6,857.23%.

  • Silence Therapeutics' FCF Margin fell 514355.00% to 6,857.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 281.06%, marking a year-over-year decrease of 3472.00%. This contributed to the annual value of 156.85% for FY2024, which is 36.00% down from last year.
  • Per Silence Therapeutics' latest filing, its FCF Margin stood at 6,857.23% for Q3 2025, which was up 29.67% from 9,749.55% recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' FCF Margin registered a high of 963.75% during Q2 2021, and its lowest value of 9,749.55% during Q2 2025.
  • Moreover, its 3-year median value for FCF Margin was 686.75% (2024), whereas its average is 2,646.58%.
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 75,238bps in 2024, then tumbled by 906,280bps in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' FCF Margin stood at 64.59% in 2021, then tumbled by 336bps to 281.39% in 2022, then crashed by 206bps to 861.22% in 2023, then skyrocketed by 87bps to 108.84% in 2024, then crashed by 6,200bps to 6,857.23% in 2025.
  • Its FCF Margin was 6,857.23% in Q3 2025, compared to 9,749.55% in Q2 2025 and 8,671.13% in Q1 2025.